Sanofi India Ltd

BSE: SANOFI500674ISIN INE058A01010

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹3,450.75+67.50 (+2.00%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹4,788.70
52W low: ₹2,758.30
Off 52W high: -27.94%
1M return: +14.06%
3M return: +3.63%
6M return: +1.58%
1Y return: -27.39%
20D avg volume: 2,662
50 DMA: ₹3,082.24
200 DMA: ₹3,407.67

Key ratios Consolidated

Market cap: ₹7,947 Cr
Current price: ₹3,450.75
52W high / low: ₹4,788.70 / ₹2,758.30
Face value: ₹10.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: —
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: 288.60
Dividend yield: 3.56%
Dividend / share (TTM): ₹123.00
Payout: —
Cash conversion cycle: —

Financials

Metric	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24
Income statement
	514.90	524.00	463.50	732.40	693.90	714.58	706.10
	5.90	2.30	4.80	6.50	12.00	11.82	15.70
	520.80	526.30	468.30	738.90	705.90	726.40	721.80
	406.60	413.71	357.20	523.80	517.10	516.52	538.40
	102.70	93.10	82.10	143.70	133.50	130.99	154.40
	238.50	201.80	92.50	40.80	134.60	395.22	188.50
	53.80	56.70	60.20	92.40	91.90	93.14	93.70
	0.40	0.40	0.40	0.30	0.40	0.32	0.70
	9.60	9.00	9.00	10.00	10.20	9.88	9.80
	93.00	87.64	66.50	112.70	134.30	113.41	117.90
	114.20	112.59	111.10	215.10	188.80	209.88	183.40
	8.00	0.00	-19.00	-26.70	0.00	0.00	0.00
	122.20	112.59	92.10	188.40	188.80	209.88	183.40
	30.90	30.40	23.90	51.80	51.10	57.93	60.50
	91.30	82.19	103.20	136.60	137.70	151.95	122.90
	39.64	35.69	29.62	59.31	59.79	65.95	53.37
Key metrics
	132.20	121.99	101.50	198.70	199.40	220.08	193.90
	25.70%	23.30%	21.90%	27.10%	28.70%	30.80%	27.50%
	17.70%	15.70%	22.30%	18.70%	19.80%	21.30%	17.40%
	-25.80%	-26.70%	-34.40%	—	—	—	—
	-33.70%	-45.90%	-16.00%	—	—	—	—

Metric	TTM	FY25	FY24
Income statement
	2,235	2,013	2,851
	19.50	16.50	65.30
	2,254	2,030	2,916
	1,701	1,561	2,089
	421.60	354.80	564.40
	573.60	564.30	929.00
	263.10	240.20	370.60
	1.50	1.50	1.70
	37.60	36.70	39.60
	359.84	302.90	475.80
	552.99	469.10	827.70
	-37.70	-37.70	17.80
	515.29	431.40	845.50
	137.00	117.70	242.60
	413.29	413.30	602.90
	164.26	136.21	261.78
Key metrics
	554.39	469.60	886.80
	24.81%	23.30%	31.10%
	18.49%	20.50%	21.10%
	—	-29.40%	—
	—	-31.40%	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	491.70	437.70	472.30	419.80	475.40	406.30	535.90	514.90	524.00	463.50	732.40	693.90
	5.50	6.20	4.40	2.80	4.90	8.70	3.30	5.90	2.30	4.80	6.50	12.00
	497.20	443.90	476.70	422.60	480.30	415.00	539.20	520.80	526.30	468.30	738.90	705.90
	339.50	331.60	338.80	339.60	350.70	320.90	373.90	406.60	413.71	357.20	523.80	517.10
	73.60	57.30	50.30	55.30	53.30	62.10	75.70	102.70	93.10	82.10	143.70	133.50
	227.40	158.90	148.20	124.50	269.80	35.60	84.10	238.50	201.80	92.50	40.80	134.60
	39.70	44.60	42.80	44.70	41.90	44.90	53.80	53.80	56.70	60.20	92.40	91.90
	0.20	0.30	0.30	0.60	0.40	0.40	0.30	0.40	0.40	0.40	0.30	0.40
	8.80	8.90	9.00	9.50	9.10	9.10	9.60	9.60	9.00	9.00	10.00	10.20
	52.80	52.60	52.40	76.70	59.40	57.80	69.70	93.00	87.64	66.50	112.70	134.30
	157.70	112.30	137.90	83.00	129.60	94.10	165.30	114.20	112.59	111.10	215.10	188.80
	0.00	0.00	0.00	0.00	-27.30	0.00	0.00	8.00	—	-19.00	-26.70	—
	157.70	112.30	137.90	83.00	102.30	94.10	165.30	122.20	112.59	92.10	188.40	188.80
	41.00	28.80	35.30	21.30	26.30	24.60	45.80	30.90	30.40	23.90	51.80	51.10
	116.70	83.50	102.60	61.70	76.00	69.50	119.50	91.30	82.19	103.40	136.60	137.70
	50.67	36.26	44.55	26.79	32.99	30.18	51.89	39.64	35.69	29.62	59.31	59.79
Key metrics
	166.70	121.50	147.20	93.10	111.80	103.60	175.20	132.20	121.99	101.50	198.70	199.40
	33.90%	27.80%	31.20%	22.20%	23.50%	25.50%	32.70%	25.70%	23.30%	21.90%	27.10%	28.70%
	23.70%	19.10%	21.70%	14.70%	16.00%	17.10%	22.30%	17.70%	15.70%	22.30%	18.70%	19.80%
	—	13.40%	—	11.00%	—	11.60%	—	—	—	—	—	—
	3.40%	7.70%	-11.90%	-18.50%	-9.30%	-12.30%	-26.80%	-25.80%	—	—	—	—
	53.60%	20.10%	-14.10%	-32.40%	-7.50%	-32.80%	-12.50%	-33.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,822	1,837	2,013	2,851	2,770	2,957
	18.90	19.70	16.50	65.30	71.50	74.40
	1,840	1,857	2,030	2,916	2,842	3,031
	1,350	1,385	1,561	2,088	2,109	2,263
	236.50	246.40	354.80	564.40	549.70	555.10
	659.00	514.00	564.30	929.00	651.00	708.60
	171.80	185.30	240.20	370.60	405.90	433.90
	1.40	1.70	1.50	1.70	1.70	1.80
	36.20	37.30	36.70	39.60	41.90	66.70
	234.50	263.60	302.90	475.50	470.20	453.40
	490.90	472.00	469.10	828.00	732.30	768.40
	0.00	-27.30	-37.70	17.80	132.00	489.20
	490.90	444.70	431.40	845.80	864.30	1,258
	126.40	118.00	117.70	242.60	243.70	313.20
	364.50	326.70	413.50	603.20	620.60	944.40
	158.27	141.85	136.21	261.91	269.47	410.06
Key metrics
	528.50	483.70	469.60	887.10	907.90	1,326
	29.01%	26.30%	23.30%	31.10%	32.80%	44.90%
	20.01%	17.80%	20.50%	21.20%	22.40%	31.90%
	-5.74%	-8.70%	-29.40%	2.90%	-6.30%	—
	2.30%	-21.00%	-31.40%	-2.80%	-34.30%	—
	—	412.60	—	—	—	—
	—	1.34	—	—	—	—
Cash flow
	—	438.30	—	—	—	—
	—	-11.30	—	—	—	—
	—	-447.90	—	—	—	—
	—	25.70	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -12.79%
Sales CAGR 5Y: —
Profit CAGR 3Y: -19.26%
Profit CAGR 5Y: —
Sales YoY (TTM): -5.74%
Profit YoY (TTM): +2.30%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 60.40%

Quarter	September 2026	June 2026
Promoter %	60.40%	60.39%

Holder	Type	Holding	Previous	Change
HOECHST GMBH	Promoter	45.18%	60.37%	-15.19%
Sanofi Healthcare India Private Limited	Promoter Group	15.20%	0.00%	+15.20%
LIFE INSURANCE CORPORATION OF INDIA - P & GS Fund	Public	5.95%	5.95%	0.00%
NIPPON LIFE INDIA TRUSTEE LTD- A/C NIPPON INDIA GROWTH MID CAP FUND	Public	4.17%	—	—
GENERAL INSURANCE CORPORATION OF INDIA	Public	2.56%	2.56%	0.00%
ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA SUN LIFE LARGE CAP FUND	Public	2.04%	—	—
BAJAJ LIFE INSURANCE LIMITED	Public	1.44%	1.44%	0.00%
SBI CONTRA FUND	Public	1.09%	—	—
SANOFI	Promoter	0.02%	0.02%	0.00%
Sanofi (China) Investment Co. Ltd.	Promoter Group	0.00%	0.00%	0.00%
Sanofi Aventis de Colombia S.A.	Promoter Group	0.00%	0.00%	0.00%
Sanofi Cathay (Shanghai) Private Equity Investment Fund Partnership (L.P.)	Promoter Group	0.00%	0.00%	0.00%
Sanofi R&D Vaccins	Promoter Group	0.00%	0.00%	0.00%
Sanofi Aventis del Peru S.A	Promoter Group	0.00%	0.00%	0.00%
Sanofi sp. z.o.o.	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Sanofi India Ltd S	7,947	3,450.75	21.80	—	-5.74% TTM	+2.30% TTM	-27.39%

Filings & corporate actions

Recent announcements

Kindly refer the attachment30 Oct 2026 · Company Update / Newspaper Publication
Kindly refer the attachment29 Oct 2026 · Company Update / General
Kindly refer the attachment29 Oct 2026 · Corp Action / Dividend Updates
Kindly refer the attachment29 Oct 2026 · Corp. Action / Record Date
Kindly refer the attachment29 Oct 2026 · Corp. Action / Dividend
Kindly refer the attachment29 Oct 2026 · Company Update / Press Release / Media Release
Kindly refer the attachment29 Oct 2026 · Board Meeting / Outcome of Board Meeting
Kindly refer the attachment29 Oct 2026 · Result / Financial Results
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....19 Oct 2026 · Board Meeting / Board Meeting
Kindly refer the attachment.9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(iii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....7 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
Kindly refer the attachment.29 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd28 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
Disclosure received by the Company on 25th September 2026 under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Sanofi Healthcare India Private Limited, ....28 Sep 2026 · Company Update / General
Disclosure received by the Company on 25th September 2026 under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from Hoechst GmbH, a promoter of the Company28 Sep 2026 · Company Update / General
Kindly refer the attachment25 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hoechst GmbH & PACs25 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd & PACs25 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd & PACs25 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hoechst GmbH & PACs25 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Kindly refer the attachment.25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Kindly refer the attachment21 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....18 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011
Kindly refer the attachment8 Sep 2026 · Company Update / General
Kindly refer the attachment31 Aug 2026 · Company Update / General
Kindly refer the attachment13 Aug 2026 · Company Update / General
Kindly refer the attachment11 Aug 2026 · Company Update / General
Kindly refer the attachment.10 Aug 2026 · Company Update / Earnings Call Transcript
Kindly refer the attachment6 Aug 2026 · Company Update / Analyst / Investor Meet
Kindly refer the attachment5 Aug 2026 · Company Update / Newspaper Publication
Kindly refer the attachment5 Aug 2026 · Company Update / Investor Presentation
Kindly refer the attachment4 Aug 2026 · Company Update / General
Kindly refer the attachment4 Aug 2026 · Company Update / General
Kindly refer the attachment4 Aug 2026 · Company Update / Press Release / Media Release
Kindly refer the attachment4 Aug 2026 · Board Meeting / Outcome of Board Meeting
Kindly refer the attachment4 Aug 2026 · Result / Financial Results
Kindly refer the attachment31 Jul 2026 · Company Update / Change in Management
Kindly refer the attachment.23 Jul 2026 · Company Update / Analyst / Investor Meet
Kindly refer the attachment23 Jul 2026 · Company Update / Resignation of Director
Kindly refer the attachment23 Jul 2026 · Company Update / Resignation of Chief Financial Officer (CFO)

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 75.0000	5 Nov 2026	5 Nov 2026	—
Final Dividend - Rs. - 48.0000	22 Apr 2026	22 Apr 2026	—
Interim Dividend - Rs. - 75.0000	7 Nov 2025	7 Nov 2025	—
Final Dividend - Rs. - 117.0000	25 Apr 2025	25 Apr 2025	—

Board meetings

4 Aug 2026 Board Meeting - Financial Results